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Abstract
The Epstein-Barr virus (EBV) latent-lytic switch is mediated by the BZLF1 immediate-early protein. EBV is normally latent in
memory B cells, but cellular factors which promote viral latency specifically in B cells have not been identified. In this report,
we demonstrate that the B-cell specific transcription factor, Oct-2, inhibits the function of the viral immediate-early protein,
BZLF1, and prevents lytic viral reactivation. Co-transfected Oct-2 reduces the ability of BZLF1 to activate lytic gene
expression in two different latently infected nasopharyngeal carcinoma cell lines. Furthermore, Oct-2 inhibits BZLF1
activation of lytic EBV promoters in reporter gene assays, and attenuates BZLF1 binding to lytic viral promoters in vivo. Oct-2
interacts directly with BZLF1, and this interaction requires the DNA-binding/dimerization domain of BZLF1 and the POU
domain of Oct-2. An Oct-2 mutant (D262–302) deficient for interaction with BZLF1 is unable to inhibit BZLF1-mediated lytic
reactivation. However, an Oct-2 mutant defective for DNA-binding (Q221A) retains the ability to inhibit BZLF1 transcriptional
effects and DNA-binding. Importantly, shRNA-mediated knockdown of endogenous Oct-2 expression in several EBV-positive
Burkitt lymphoma and lymphoblastoid cell lines increases the level of lytic EBV gene expression, while decreasing EBNA1
expression. Moreover, treatments which induce EBV lytic reactivation, such as anti-IgG cross-linking and chemical inducers,
also decrease the level of Oct-2 protein expression at the transcriptional level. We conclude that Oct-2 potentiates
establishment of EBV latency in B cells.
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Introduction
Epstein-Barr virus (EBV) is the causative agent of infectious
mononucleosis and is widely prevalent within the human
population, infecting greater than 90% of all individuals [1,2].
The virus is also associated with several different diseases,
including, but not limited to, Burkitt lymphoma (BL), Hodgkin
disease (HD), nasopharyngeal carcinoma (NPC), T/NK lympho-
ma, and gastric carcinoma [1,3]. Like all herpesviruses, EBV
infection of cells can result in either lytic replication or latency. In
the normal host, memory B cells serve as the primary reservoir of
latent EBV infection, while oropharyngeal epithelial cells support
the lytic form of infection [1,2,4–8]. EBV can also be reactivated
to the lytic form when infected memory B cells, stimulated by
antigen, differentiate into plasma cells [9]. While both the latent
and lytic forms of infection are essential for the long-term success
of EBV, the specific cellular factors that determine the very
different outcomes following EBV infection in B cells versus
epithelial cells remain poorly defined.
Several different types of EBV latency have been described [2].
Type III latency is characterized by the expression of all nine EBV
latent proteins (EBNA1, EBNA2, EBNA3A-C, EBNA-LP, LMP1,
LMP2A-B), and occurs in EBV-transformed lymphoblastoid B-cell
lines (LCLs), as well as some BL lines in culture [10,11]. In cells
with the most restricted form of viral latency, known as type I
(characteristic of BL tumors in vivo), the only viral protein
expressed is EBNA1. The EBNA1 transcript is derived from the
viral Q promoter (Qp) in cells with type I latency, versus the C
promoter (Cp) in cells with type III latency [12]. Cellular factors
that determine the type of viral latency are not currently well
understood.
EBV lytic reactivation can be initiated by expression of either
the BZLF1 (Z, Zta, ZEBRA, EB1) or BRLF1 (R, Rta) immediate-
early (IE) viral gene products [13–19]. The BZLF1 and BRLF1
proteins are transcription factors which activate each other’s
promoters, as well as their own promoters [18–26]. This enables
the virus to amplify weak lytic induction stimuli. BZLF1 binds to
AP1 DNA sites, as well as AP1-like sites termed ZREs (BZLF1-
responsive elements), that are found in many early lytic EBV viral
promoters, including the BZLF1 and BRLF1 promoters [23,24].
Interestingly, CpG methylation of many promoters containing
ZREs results in increased BZLF1 binding and transactivation of
these promoters [25,27,28]. BRLF1 binds to a GC-rich motif and
activates some lytic viral promoters through a direct DNA-binding
mechanism [29–33], although BRLF1 activation of some viral
promoters (including the BZLF1 promoter) occurs though indirect
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(and for some genes synergistically) activate expression of the
entire lytic viral gene program, leading to productive lytic viral
replication [21,23,30,33–39]. Since both BZLF1 and BRLF1 are
required to activate many of the lytic viral genes, BZLF1 must first
turn on BRLF1 expression (and vice versa) to successfully induce
full lytic reactivation in the context of the intact viral genome.
Cellular transcription factors that regulate the activity of the
BZLF1 and/or BRLF1 promoters play a major role in
determining the level of lytic gene expression [1,2]. For example,
ZEB1 promotes viral latency by binding directly to, and inhibiting
transcription of, the BZLF1 promoter [40–43]. Conversely, the
activated form of XBP1 (XBP1-s), which is expressed during
plasma cell differentiation, activates both the BZLF1 and BRLF1
promoters, thereby intiating the viral lytic cycle [44,45].
Stimulation of the B-cell receptor with anti-IgG induces a signal
transduction cascade that results in lytic reactivation in BL lines,
and this effect is at least partially mediated through phosphatidy-
linositol 3-kinase/Ca
2+ -induced dephosphorylation of the
MEF2D protein (converting it from a negative to positive regulator
of the BZLF1 promoter) [46]. In addition, the TGF-b cytokine
induces lytic reactivation in some BL lines by promoting SMAD2/
3/4-mediated activation of the BZLF1 promoter [47].
Cellular factors that regulate the function of the BZLF1 and/or
BRLF1 proteins also influence the abililty of the virus to reactivate
[36,48–54]. For example, we recently demonstrated that the POU
domain transcription factor, Oct-1, enhances BRLF1 transcrip-
tional function and DNA-binding through a direct protein-protein
interaction between Oct-1 and BRLF1 [55]. In addition, the
TORC2 protein promotes BZLF1 function, while the p65
component of NFkB inhibits BZLF1 function, through direct
protein-protein interactions with the BZLF1 protein [51,54].
However, cellular proteins that promote viral latency in a B-cell
specific manner have not yet been identified.
The POU domain transcription factors contain a conserved
POU domain which mediates protein-protein interactions and
binds to the octamer DNA motif (consensus site ATGCAAAT)
[56–58]. In addition to its effect on EBV reactivation [55], the
POU domain family member Oct-1 also promotes lytic gene
expression of several other herpesviruses. The Kaposi Sarcoma
Herpesvirus (KSHV) ORF50 (Rta) immediate-early protein
interacts directly with Oct-1, and this interaction is required for
ORF50 activation of the early lytic K-bZIP (K8) promoter, as well
as its own promoter, in certain cell lines [59,60]. In addition, Oct-
1 interaction with the herpes simplex virus (HSV) and varicella
zoster virus (VZV) encoded tegument proteins (VP16 and ORF10
respectively), is required for efficient activation of the HSV and
VZV immediate-early promoters [61–65].
Oct-2, like Oct-1, is a member of the POU (Pit-Oct-Unc)
domain family [66–69]. In contrast to the ubiquitously expressed
Oct-1 protein, Oct-2 expression is restricted to B cells and
neuronal cells [66–69]. As opposed to the effect of Oct-1, Oct-2
has been reported to inhibit lytic KSHV reactivation by
competing for Oct-1 binding sites in the KSHV ORF50 promoter
[70]. Furthermore, certain isoforms of Oct-2 (preferentially
expressed in neuronal cells) promote HSV latency in neurons by
binding to, and repressing, the ICP0 IE promoter [71].
Oct-2 can act as either a positive or negative regulator of
transcription, depending upon its interaction with co-activators
(such as Bob-1) [72,73] versus co-repressors (such TLE1/2) [74].
In the case of EBV, the cellular Oct-2 transcription factor has
been proposed to promote type I (versus type III) latency by
binding to the FR repeat elements (in conjunction with TLE
family members) and inhibiting the activity of the downstream
Cp type III latency promoter [74,75]. However, another report
suggested that Oct-2 binding to the FR repeats enhances the
activity of the Cp [72]. Furthermore, since the previous reports
were based upon the results of reporter gene assays and over-
expressed Oct-2, the effect of endogenous Oct-2 upon the
regulation of EBV gene expression in the context of the intact
viral genome has remained uncertain.
In this paper we have examined the hypothesis that the Oct-2
transcription factor promotes EBV latency in a B-cell specific
manner. Oct-2 expression is decreased following B-cell differen-
tiation into plasma cells [76], making it an attractive candidate to
negatively regulate EBV lytic reactivation. To date, however, the
role of Oct-2 in regulating EBV lytic gene expression has not been
investigated. Here we show that Oct-2 inhibits EBV lytic
reactivation by attenuating BZLF1 function. We find that Oct-2
directly interacts with BZLF1 in vitro and in vivo, and inhibits
BZLF1 binding to EBV promoters in vivo. A DNA-binding
defective Oct-2 mutant (Q221A) retains the ability to inhibit
BZLF1 function. Furthermore, we show that shRNA-mediated
knockdown of endogenous Oct-2 increases lytic protein expression
(while decreasing EBNA1) in EBV-positive B-cell lines with either
type I or type III latency. Finally, we show that two different lytic
inducing stimuli (anti-IgG and 12-O-tetradecanoyl-phorbol-13-
acetate (TPA)/sodium butyrate) also decrease expression of
endogenous Oct-2 in EBV-infected B cells. Together, these results
indicate that Oct-2 acts as a potent negative regulator of EBV lytic
reactivation, and suggest a mechanism by which EBV latency is
specifically promoted in B cells.
Results
Oct-2 inhibits BZLF1-mediated lytic viral reactivation
We recently reported that the ubiquitous Oct-1 transcription
factor promotes lytic EBV reactivation [55]. To determine if the
B-cell specific Oct-2 transcription factor has a similar effect, we
transfected either a BZLF1 or BRLF1 expression vector, in the
presence or absence of a co-transfected Oct-2 vector (expressing
the major B-cell form of Oct-2, isoform 1), into latently infected
EBV-positive HONE-Akata NPC cells. Immunoblot analysis was
performed two days after transfection to assess the level of
Author Summary
Epstein-Barr virus (EBV) is a human herpesvirus associated
with B-cell malignancies. EBV infection of cells can result in
either lytic replication or latency. Memory B cells are the
primary site of EBV latency within the human host, while
oropharyngeal epithelial cells support the lytic form of
infection. However, the cellular mechanism(s) that enable
EBV to establish viral latency in a B-cell specific manner are
not currently understood. In this report, we show that the
B-cell specific cellular transcription factor, Oct-2, promotes
viral latency by inhibiting the lytic form of infection. We
find that Oct-2 interacts directly with the EBV immediate-
early protein, BZLF1, and abrogates its ability to activate
lytic viral gene transcription through protein-protein
interactions off the DNA. Furthermore, knockdown of
endogenous Oct-2 expression in several latently-infected
Burkitt lymphoma B-cell lines increases EBV lytic protein
expression. In addition, we show that certain stimuli which
can prompt lytic EBV reactivation in B cells also decrease
expression of endogenous Oct-2. Our results suggest that
the cellular transcription factor, Oct-2, promotes EBV
latency in a B-cell dependent manner.
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induce expression of lytic EBV proteins from the endogenous viral
genome.
In contrast to the previously reported effect of Oct-1 [55], co-
transfected Oct-2 greatly reduced BZLF1-mediated activation of
the BRLF1 IE protein, as well as the early lytic BMRF1 protein
(Figure 1A). In contrast, co-transfected Oct-2 did not affect the
ability of BRLF1 to activate expression of BZLF1 from the
endogenous viral genome; however, the ability of BRLF1 to
activate expression of the early viral protein, BMRF1, from the
endogenous viral genome was reduced (Figure 1B). Since the
BMRF1 promoter is known to require both BZLF1 and BRLF1
function to be activated efficiently in the context of the intact viral
genome [21,34], these results are consistent with a model in
which Oct-2 primarily inhibits BZLF1 (rather than BRLF1)
function.
The experiments shown in Figures 1A and B (which used
500 ng of transfected Oct-2 expression vector per 12-well dish),
resulted in Oct-2 expression levels greatly above that found in
EBV-infected B cells (data not shown). To determine if Oct-2 can
inhibit BZLF1 function when expressed at a level in HONE-Akata
cells similar to that expressed in EBV-infected BL cells, we
transfected different amounts of Oct-2 into HONE-Akata cells and
performed western blots to compare the Oct-2 expression in the
transfected epithelial cells versus the endogenous Oct-2 level in
MutuI BL cells. These results indicated that 50 ng of transfected
Oct-2 plasmid vector results in an Oct-2 protein level in HONE-
Akata cells similar to the endogenous Oct-2 level in MutuI cells
(Figure 1C). Importantly, this level of Oct-2 expression in HONE-
Akata cells was sufficient to decrease BZLF1-mediated activation
of its own promoter, as well as BMRF1 and BRLF1 (Figure 1C).
Therefore, Oct-2 is able to inhibit lytic reactivation when
expressed at physiologic levels.
Oct-2 inhibits lytic EBV replication
To examine whether Oct-2 also decreases BZLF1-initiated viral
replication, CNE-2 Akata NPC cells were transfected with BZLF1
in the presence or absence of Oct-2. Transfected cell pellets were
examined by immunoblot analysis to determine the effect of Oct-2
on lytic protein expression in the CNE-2 Akata cells (Figure 2A),
and the amount of infectious viral particles released into the
supernatant (from the same transfection) was quantitated three
days after transfection using the green Raji cell assay (Figure 2B).
CNE-2 Akata cells are stably infected with a GFP-expressing EBV
that can be used to titer virus production.
Similar to the results in HONE-Akata cells, co-transfected Oct-
2 inhibited the ability of transfected BZLF1 to induce lytic gene
expression in CNE-2 Akata cells. Furthermore, transfected Oct-2
inhibited the amount of infectious virus produced from BZLF1-
transfected cells, as well as the level of constitutive virus
production. These results indicate that Oct-2 inhibits EBV lytic
viral replication.
Oct-2 inhibits BZLF1 activation of multiple lytic EBV
promoters in EBV-negative cells
Since the two EBV IE proteins, BZLF1 and BRLF1, activate
one another’s promoters, and cooperate to turn on expression of
many early viral genes, it is difficult to distinguish between the
effects of Oct-2 on BZLF1- versus BRLF1-mediated transcrip-
tional function in the context of the intact viral genome. We
therefore compared the effect of Oct-2 on BZLF1- versus BRLF1-
mediated activation of early lytic EBV promoters using reporter
gene assays in EBV-negative HONE-1 NPC cells. As shown in
Figures 3A–F, co-transfected Oct-2 reduced BZLF1-mediated
activation of each of the five different early lytic EBV promoters
examined. In contrast, Oct-2 did not affect BRLF1-mediated
activation of two different lytic viral promoters (Figures 3E–F).
Figure 1. Oct-2 inhibits BZLF1-mediated lytic viral reactivation. (A) EBV-positive HONE-Akata cells were transfected with 5 ng BZLF1, 500 ng
Oct-2, or control expression vectors as indicated. Immunoblot analysis was performed two days after transfection to compare the levels of transfected
Oct-2 and BZLF1, as well as the lytic viral proteins BMRF1 and BRLF1 derived from the endogenous viral genome. b-actin expression was used as a
loading control. (B) HONE-Akata cells were transfected with 5 ng BRLF1, 500 ng Oct-2, or control expression vectors as indicated. Immunoblot
analysis was performed two days after transfection to compare the levels of transfected Oct-2 and BRLF1, as well as the lytic viral proteins BMRF1 and
BZLF1 derived from the endogenous viral genome. b-actin expression was used as a loading control. (C) HONE-Akata cells were transfected with
control vector or 50 ng Oct-2 expression vector (with or without 5 ng BZLF1) as indicated. Immunoblot analysis was performed two days after
transfection to compare the levels of transfected and endogenous Oct-2 in HONE-Akata and MutuI cells, the levels of transfected BZLF1, and the lytic
viral proteins, BZLF1 (genomic BZLF1), BRLF1, and BMRF1, derived from the endogenous viral genome. b-actin served as a loading control.
doi:10.1371/journal.ppat.1002516.g001
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activation of lytic EBV promoters, and demonstrate that this effect
is independent of any other viral proteins.
Oct-2 inhibits BZLF1 DNA-binding in vivo
BZLF1 is a bZIP protein which contains an N-terminal
transcriptional activation domain and a C-terminal DNA-
binding/dimerization domain [26,37,77–81]. To further examine
the effect of Oct-2 on BZLF1 transcriptional function per se
(independent of BZLF1 DNA-binding), we performed reporter
gene assays using the pGal4-BZLF1 (1–167) construct, which
contains the transcriptional activation domain of BZLF1 fused to
the Gal4 DNA-binding domain. The pGal4-BZLF1 (1–167) vector
was co-transfected with the pGal4-E1B-CAT vector (which
contains five copies of the Gal4 binding motif upstream of the
minimal E1B promoter and CAT reporter gene) in the presence or
absence of Oct-2, and the amount of CAT activity was
determined. In contrast to its effect on BZLF1-mediated activation
of viral lytic promoters, Oct-2 had no effect on BZLF1
transcriptional function in this assay (Figure 4A). This result
indicates that Oct-2 does not inhibit the transcriptional function of
BZLF1 when its DNA-binding domain is replaced by the Gal4
DNA-binding domain, and suggests that Oct-2 may instead inhibit
BZLF1 DNA-binding activity.
We next performed ChIP assays to determine if Oct-2 inhibits
BZLF1 binding to lytic EBV gene promoters in vivo. HONE-Akata
cells were transfected with a Flag-tagged BZLF1 expression vector,
in the presence or absence of co-transfected Oct-2, and the
amount of BZLF1 binding to lytic EBV promoters was examined.
As shown in Figure 4B, co-transfected Oct-2 greatly decreased the
amount BZLF1 complexed to the BRLF1 promoter, as well as the
BMRF1 early promoter. These results suggest that Oct-2 inhibits
BZLF1 binding to lytic EBV promoters in vivo.
BZLF1 interacts directly with Oct-2 in vitro and in vivo
To determine if Oct-2 interacts directly with BZLF1, we
performed GST pull-down assays using in vitro-translated
35S-
labeled BZLF1, and bacterially produced glutathione-S-transfer-
ase (GST) or GST-Oct-2 fusion proteins (containing only the Oct-
2 POU domain, amino acids 179 to 343). Using this assay, we
found that BZLF1 associates with GST-Oct-2, but not with the
control GST protein (Figure 5A). To examine whether Oct-2 and
BZLF1 can also interact when over-expressed in vivo,w e
transfected HeLa cells with BZLF1 and/or Oct-2 expression
vectors and performed co-immunoprecipitation assays. As shown
in Figures 5B and 5C, BZLF1 and Oct-2 can be co-immunopre-
cipitated when co-expressed in HeLa cells. To confirm that
endogenous levels of BZLF1 and Oct-2 are able to interact in a B-
cell environment, the EBV-positive BL cell line, MutuI, was
treated with TGF-b to induce the lytic form of EBV infection, and
cellular extracts were co-immunoprecipitated with anti-Oct-2 or
control antibodies. BZLF1 was co-immunoprecipitated with
endogenous Oct-2 in lytically infected MutuI cells (Figure 5D).
Taken together, these results indicate that the BZLF1 and Oct-2
proteins directly interact in vitro and in vivo.
Oct-2 interacts with BZLF1 DNA-binding/dimerization
domain, and BZLF1 interacts with Oct-2 POU domain
To map the region of the BZLF1 protein required for the
BZLF1/Oct-2 interaction, GST-BZLF1 deletions were construct-
ed containing different portions of the BZLF1 protein fused to the
GST moiety (as shown in Figure 6A), and GST pull-down assays
were performed with in vitro-translated
35S-labeled Oct-2 protein.
The results of these assays showed that Oct-2 associates with the
DNA-binding/dimerization domain of BZLF1 (Figure 6B). To
identify specific BZLF1 residues required for interaction with Oct-
2, we also performed GST-Oct-2 pull-down assays using various
35S-labeled in vitro translated BZLF1 mutants that contain
alterations in the DNA-binding/dimerization domain of BZLF1.
As shown in Figure 6C, these assays identified a BZLF1 mutant,
BZLF1 (Y200E/L225E), which is defective for interaction with the
GST-Oct-2 protein, but retains the ability to interact with the
GST-BZLF1 protein. Unfortunately, the BZLF1 (Y200E/L225E)
mutant was found to be unstable when expressed in vivo (data not
shown), and thus we could not determine if this mutant loses the
ability to be inhibited by Oct-2 in vivo.
To further map the region of Oct-2 required for interaction
with BZLF1, various GST-Oct-2 constructs were made which
contain different portions of the Oct-2 POU domain (Figure 6D),
and GST pull-down assays were performed with in vitro-translated
35S-labeled BZLF1 protein. The results of these assays indicate
that Oct-2 amino acids 262 to 302 are sufficient to mediate the
interaction with BZLF1 in vitro (Figure 6E). We next generated a
mutant Oct-2 expression vector which has amino acids 262–302
Figure 2. Oct-2 inhibits lytic EBV replication. (A) CNE-2 Akata cells
were transfected with 5 ng BZLF1, 500 ng Oct-2, or control expression
vectors as indicated. Immunoblot analysis was performed to compare
the levels of transfected Oct-2 and BZLF1, as well as the lytic viral
proteins BMRF1 and BRLF1 derived from the endogenous viral genome.
b-actin expression was used as a loading control. (B) The amount of
infectious virus produced by each condition in Figure 2A was
determined using the green Raji cell assay as described in the Materials
and Methods.
doi:10.1371/journal.ppat.1002516.g002
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this Oct-2 mutant is deficient for interaction with GST-BZLF1 in
vitro.
To determine if the ability of Oct-2 to interact directly with
BZLF1 is required for its ability to inhibit BZLF1 function in vivo,
we compared the ability of the wild-type Oct-2 protein, versus the
mutant Oct-2 (D262–302) protein, to inhibit BZLF1 function in
the NPC cell line HONE-Akata. In contrast to wild-type Oct-2,
the Oct-2 (D262–302) mutant was unable to inhibit BZLF1-
mediated disruption of latency (Figure 6G).
Oct-2 DNA-binding activity is not required for Oct-2
inhibition of BZLF1 function
To examine the importance of Oct-2 DNA-binding activity on
its ability to inhibit lytic EBV reactivation, we constructed an Oct-
2 mutant altered at residue Q221, which was previously shown to
be required for DNA-binding activity [82]. The Oct-2 mutant
(Q221A) was shown to be unable to bind DNA in vitro (Figure 7A),
and was stable when expressed in vivo.
We next compared the ability of the wild-type or DNA-binding
defective mutant Oct-2 (Q221A) to inhibit BZLF1 function.
Interestingly, the Oct-2 (Q221A) mutant was similar to the wild-
type Oct-2 protein in regard to its ability to prevent BZLF1-
mediated lytic reactivation in HONE-Akata cells (Figure 7B). The
Oct-2 (Q221A) mutant was likewise similar to the wild-type Oct-2
protein in its ability to inhibit BZLF1 activation of the lytic EBV
BMRF1 promoter in a reporter gene assay (performed in the
EBV-negative B-cell line, BJAB) (Figure 7C), although the Oct-2
(D262–302) mutant was defective (consistent with results shown in
Figure 6G). Furthermore, ChIP assays performed in HONE-Akata
cells showed that both the wild-type and mutant Oct-2 (Q221A)
proteins inhibit BZLF1 binding to lytic EBV promoters
(Figure 7D). Taken together, these results suggest that Oct-2
DNA-binding activity is not required for the ability of Oct-2 to
inhibit BZLF1-mediated lytic reactivation and/or BZLF1 DNA-
binding. Instead, our findings are consistent with a model in which
a direct protein-protein interaction between Oct-2 and BZLF1
inhibits BZLF1 binding to DNA.
Using ChIP assays, we also examined whether BZLF1 has an
effect on Oct-2 DNA-binding (Figure 7E). Even when over-
expressed at a high level (3 mg/10-cm dish), BZLF1 does not affect
Oct-2 DNA-binding to either the cellular Gadd45a promoter or
the EBV genome FR repeat element located upstream of the
latency viral Cp [72]. These results also confirm that the mutant
Oct-2 (Q221A) protein is defective for DNA-binding activity in
vivo.
Loss of endogenous Oct-2 increases constitutive and
induced lytic gene expression in EBV-infected B cells
To examine the importance of endogenous Oct-2 expression on
maintenance of EBV latency in B cells, we used shRNA vectors to
knockdown Oct-2 expression in four different EBV-positive B-cell
lines. As shown in Figure 8A, shRNA-mediated loss of endogenous
Oct-2 expression in the type I BL cell line, MutuI (which has
constitutive low level lytic gene expression), resulted in increased
expression of three different lytic viral proteins: BZLF1, BRLF1,
and BMRF1. Similar results were obtained using four different
individual shRNAs directed against Oct-2. Knockdown of Oct-2
expression likewise increased lytic protein expression in another
type I BL cell line, KemI (Figure 8B).
We also examined the effect of Oct-2 knockdown in two
different EBV-positive B-cell lines with type III latency, Raji and
LCL. In the Raji BL cell line (which has no detectable constitutive
lytic viral protein expression, but can be induced to express lytic
Figure 3. Oct-2 inhibits BZLF1 activation of multiple lytic EBV promoters in EBV-negative cells. EBV-negative HONE-1 cells were
transfected with (A) BRLF1p-luciferase construct, (B) BMRF1p-luciferase construct, (C) BXLF1p-luciferase construct, or (D) BALF2p-luciferase construct
in the presence or absence of co-transfected BZLF1 (5 ng), Oct-2 (100 ng), or control vectors as indicated. The fold luciferase activity for each
condition is shown relative to control vector; the value for the activity of the promoter construct plus the vector control is set at 1. Values are given as
means 6 standard deviations of results from two replicates. EBV-negative HONE-1 cells were transfected with the (E) BMRF1p-luciferase construct or
(F) SMp-luciferase construct in the presence or absence of co-transfected BZLF1 (5 ng), BRLF1 (5 ng), Oct-2 (100 ng), or control vectors as indicted.
doi:10.1371/journal.ppat.1002516.g003
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found that loss of endogenous Oct-2 expression did not increase
the level of constitutive lytic protein expression, but greatly
increased the amount of lytic expression in response to TPA/
sodium butyrate (Figure 8C). Similar results were obtained in an
early passage lymphoblastoid cell line (LCL) (Figure 8D). These
results indicate that Oct-2 acts as a negative regulator of lytic EBV
gene expression when expressed at normal levels in B cells with
either type I or III latency.
Since lytic reactivation is initiated by activation of the BZLF1
promoter, whereas the primary effect of Oct-2 appears to be
mediated through its interaction with the BZLF1 protein, we also
examined the effect of Oct-2 knockdown (or Oct-2 over-
expression) on certain cellular transcription factors that have been
previously shown to play important roles in regulating lytic
reactivation through effects on BZLF1 promoter activity
[41,42,46,47]. As shown in Figure S1, we did not find that
altering the level of Oct-2 in B cells (via Oct-2 knockdown) or in
epithelial cells (via Oct-2 over-expression) had a consistent effect
on the phosphorylation status of MEF-2D, the amount of ZEB1,
or SMAD2 phosphorylation. These results suggest that Oct-2 does
not induce lytic reactivation through additional effects on the
BZLF1 promoter per se, and are consistent with the results in
Figure 8 showing that Oct-2 knockdown alone is not sufficient to
induce lytic reactivation in tightly latent B-cell lines such as Raji.
Finally, we used quantitative RT-PCR (qRT-PCR) to measure
the effect of Oct-2 knockdown (in MutuI cells) on RNA levels of a
wide variety of different EBV genes (Figure 8E). The results of this
analysis indicate that following Oct-2 knockdown, the great
majority of early and late lytic EBV genes have increased RNA
expression (up to 20-fold elevated). Interestingly, as previously
reported following anti-IgG mediated lytic induction of Akata cells
[83], some viral latency gene transcripts were also increased
following Oct-2 knockdown mediated lytic induction in MutuI
cells (Figure 8E).
Lytic reactivation stimuli decrease Oct-2 expression
To determine if endogenous Oct-2 levels in B cells are affected
by stimuli known to result in lytic EBV reactivation, we treated
EBV-positive and EBV-negative BL Akata cells with or without
anti-IgG (to induce cross-linking of the B-cell receptor). We found
that the Oct-2 protein level is decreased in response to anti-IgG
treatment in the presence or absence of the EBV genome
(Figure 9A). Furthermore, the decrease in Oct-2 expression
following anti-IgG treatment in EBV-positive Akata cells was
apparent prior to the time point of maximal BMRF1 induction,
suggesting that loss of Oct-2 contributes to BZLF1 activation of
viral early genes (Figure 9B). We also examined the effect of TPA/
sodium butyrate treatment on Oct-2 expression in the Type III BL
cell line, Raji. As shown in Figure 9C, Oct-2 was decreased
following TPA/sodium butyrate treatment.
To determine whether the decreased Oct-2 expression is due to
impaired transcription versus a post-transcriptional mechanism,
we examined the level of Oct-2 RNA transcripts in the Akata-
EBV+ and Raji cells treated with or without lytic inducing stimuli
(Figure 9D). Oct-2 RNA levels were greatly diminished by both
types of lytic induction agents (anti-IgG and TPA/sodium
butyrate), suggesting that loss of Oct-2 expression is likely
mediated through a transcriptional mechanism.
Finally, to examine whether the loss of Oct-2 expression plays
any role in the ability of TPA/sodium butyrate to induce lytic
EBV gene expression in Raji cells, we stably infected Raji cells
with control or Oct-2 expressing lentiviral vectors, in an attempt to
restore Oct-2 expression in the TPA/butyrate treated cells. As
shown in Figure 9E, cells infected with the WT or mutant Oct-2
(Q221A) lentiviral vectors expressed a higher level of Oct-2 than
the vector control cells following treatment with TPA/sodium
butyrate (presumably because the MSCV promoter driving Oct-2
expression in the lentiviral vector is resistant to the inhibitory
effect), although full restoration of Oct-2 expression was not
achieved. Nevertheless, even partial restoration of WT or mutant
Figure 4. Oct-2 inhibits BZLF1 DNA-binding in vivo. (A) HeLa cells
were transfected with a Gal4-E1B-CAT construct in the presence or
absence of cotransfected Gal4-BZLF1 (1–167), Oct-2, or control vectors.
The relative CAT activity for each condition is shown; the value for the
activity of the promoter construct plus BZLF1 is set at 100. Values are
given as means 6 standard deviations of results from two independent
experiments. (B) (Upper panel) A ChIP assay was performed using
HONE-Akata cells transfected with Flag-tagged-BZLF1, Oct-2, or control
vectors as indicated. Cross-linked DNA-protein complexes were
immunoprecipitated using antibodies against Flag (BZLF1) or an IgG
control. Antibody-bound DNA sequences were then PCR-amplified
using primers spanning the EBV BRLF1 and BMRF1 promoters, or the
GAPDH gene (negative control). (Lower panel) Binding bands were
quantified using ImageJ software and represented as numerical values
in bar diagrams in the lower panel. The amount of BZLF1 binding to
each promoter in the presence or absence of Oct-2 was compared to
input.
doi:10.1371/journal.ppat.1002516.g004
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induction effect of TPA/sodium butyrate (Figure 9E). Together,
these results suggest that loss of Oct-2 expression may facilitate the
ability of certain lytic inducing agents to reactivate lytic EBV gene
expression in latently infected B cells.
Oct-2 knockdown decreases EBNA1 protein expression in
cells with type I and type III latency
Finally, since Oct-2 binding to the FR repeat element in the
viral genome has been proposed to both decrease [74] or increase
[72] the activity of the downstream Cp (which drives expression of
the EBNA genes during type III latency), we examined the effect
of Oct-2 knockdown on latent protein expression in type I versus
type III EBV-positive cell lines. Interestingly, knockdown of Oct-2
reduced EBNA1 protein expression in cell lines with both type I
and type III latency (Figure 10A). EBNA2 and EBNA-LP, which
are also driven by the Cp , were also decreased following Oct-2
repression in type III cell lines, although LMP1 was not affected.
However, the level of EBNA1 RNA was not decreased by loss of
endogenous Oct-2 in cells with either type III (Figure 10B) or type
I (Figure 8E) latency, suggesting that the Oct-2 effect on EBNA1
protein expression is primarily mediated through a post-transcrip-
tional mechanism.
While loss of Oct-2 expression was not found to influence the
type of viral latency, the finding that EBNA1 protein expression is
dependent upon continued Oct-2 expression nevertheless provides
further support for the notion that Oct-2 plays an essential role in
promoting viral latency in B cells. Consistent with this notion, we
found that long-term knockdown of Oct-2 in EBV-infected BL
and LCL lines was incompatible with prolonged viability, and that
such cell lines were dead within 14 days or had restored Oct-2
expression (data not shown). Together, these findings suggest that
in addition to repressing lytic gene expression, Oct-2 may promote
EBV latency by enhancing EBNA1 protein expression in both type
I and type III latent infections.
Discussion
The latent form of EBV infection ensures the long-term survival
of the virus within the human host, and is an essential aspect of the
viral life cycle. Although B cells are known to be the major site of
viral latency [4,6], the specific cellular transcription factor(s) that
promote viral latency in a B-cell dependent manner have not been
identified. In this report, we show that the B-cell specific
transcription factor, Oct-2, promotes viral latency by directly
Figure 5. BZLF1 interacts directly with Oct-2 in vitro and in vivo.
(A) (Left panel) GST pull-down assays were performed using GST or GST-
Oct-2 fusion proteins incubated with
35S-labeled, in vitro-translated
BZLF1 protein. Twenty percent of the direct load was used for
autoradiography. (Right panel) A Coomassie stain demonstrating the
levels of GST or GST-Oct-2 protein used in the GST pull-down assays. (B
and C) EBV-negative HeLa cells were transfected with Oct-2 in the
presence or absence of co-transfected BZLF1 and then immunoprecip-
itated with (B) a control mouse antibody or anti-BZLF1 mouse antibody
or (C) a control rabbit antibody or anti-Oct-2 rabbit antibody. Five
percent of the direct load was used for immunoblot analysis.
Immunoprecipitated proteins were then examined by immunoblot
analysis using anti-BZLF1 or anti-Oct-2 antibodies as indicated. The
amount of BZLF1 and Oct-2 protein pulled down for each condition was
quantitated relative to the corresponding input and is shown as a
numerical value below each immunoblot; the amount of input for each
condition was set at 100. (D) EBV-positive BL MutuI (type I latency) cells
were treated with or without 5 mg/mL TGF-b for 24 hours and then
immunoprecipitated with a control rabbit or Oct-2 rabbit antibody.
Immunoprecipitated proteins were then examined by immunoblot
analysis using anti-BZLF1 or anti-Oct-2 antibodies as indicated. Five
percent of the direct load was used for immunoblot analysis. The
amount of BZLF1 and Oct-2 protein pulled down for each condition was
quantitated relative to the corresponding input and is shown as a
numerical value below each immunoblot; the amount of input for each
condition was set at 100.
doi:10.1371/journal.ppat.1002516.g005
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of the BZLF1 protein transcriptional activation (TA), basic DNA-binding (DNA), dimerization (DIM), and C-terminal tail (Tail) domains. Numbers
represent amino acid positions. Full-length (FL), as well as various BZLF1 truncation proteins used in subsequent GST pull-down assays are also
depicted. (B) GST pull-down assays were performed using GST, GST-Oct-2, or various GST-BZLF1 truncation fusion proteins incubated with
35S-
labeled, in vitro-translated Oct-2 protein. Twenty percent of the direct load was used for autoradiography. The amount of Oct-2 binding in each
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protein.
Our results here show that Oct-2 inhibits BZLF1-mediated lytic
reactivation in two different latently infected, EBV-positive NPC
cell lines (HONE-Akata and CNE-2 Akata) (Figures 1 and 2). Oct-
2 also abrogates both constitutive, and BZLF1-induced, lytic viral
replication (Figure 2). Using reporter gene assays in EBV-negative
cells, we demonstrate that Oct-2 inhibits BZLF1-mediated, but not
BRLF1-mediated, activation of several different early lytic EBV
promoters (Figure 3). Thus, the primary target of the Oct-2
inhibitory effect appears to be the BZLF1 protein.
To further explore the mechanism(s) by which Oct-2 reduces
BZLF1-mediated activation, we examined the effect of Oct-2 on
BZLF1 transcriptional function (using a construct in which the
BZLF1 DNA-binding domain is replaced by the GAL4 DNA-
binding domain), versus BZLF1 DNA-binding activity (Figure 4).
Oct-2 was not found to affect BZLF1 transcriptional function per
se. However, ChIP assays revealed that Oct-2 inhibits BZLF1
binding to early lytic EBV promoters in vivo.
We next asked if the Oct-2 and BZLF1 proteins directly
interact. We indeed detected an interaction between the Oct-2
and BZLF1 proteins using both in vivo co-immunoprecipitation
assays, as well as in vitro GST-fusion protein pull-down assays
(Figure 5). Importantly, since we could also detect the interaction
between endogenous BZLF1 and Oct-2 proteins in TGF-b treated
MutuI cells (Figure 5), the Oct-2/BZLF1 interaction is not an
artifact of over-expression systems. These results suggest that Oct-
2 attenuates BZLF1 function by directly interacting with the
BZLF1 protein and inhibiting its DNA-binding activity.
To further define the nature of the Oct-2/BZLF1 interaction,
we mapped the regions of BZLF1 and Oct-2 required for this
interaction (Figure 6). The region of BZLF1 encompassing its basic
DNA-binding domain and the adjacent bZIP dimerization
domain (residues 170 to 225) was found to be sufficient for
BZLF1 interaction with Oct-2. In addition, our results showed that
a 41 amino acid stretch (residues 262 to 302) within the POU
domain of Oct-2 is sufficient for its interaction with BZLF1. By
using an Oct-2 mutant (D262–302) which lacks the region
required to interact with BZLF1, we confirmed that a direct
interaction between Oct-2 and BZLF1 is required for Oct-2
inhibition of BZLF1 transcriptional function.
The findings that Oct-2 inhibits BZLF1 DNA-binding activity,
and that an Oct-2 mutant (D262–302) that is unable to interact
with BZLF1 is unable to inhibit BZLF1-mediated lytic reactiva-
tion, suggest a model in which Oct-2 inhibits BZLF1 function by
forming an Oct-2/BZLF1 complex that cannot bind to BZLF1-
response elements in EBV lytic promoters. To gain further support
for this model (and since we were unable to identify a stable
BZLF1 mutant that is specifically defective for the Oct-2
interaction), we next determined whether the DNA-binding
activity of Oct-2 is required for its ability to inhibit BZLF1
function. Using a DNA-binding defective mutant, Oct-2 (Q221A),
we showed that Oct-2 DNA-binding activity is not required for its
ability to inhibit BZLF1 function (Figure 7). This result strongly
suggests that Oct-2 inhibits BZLF1 function through a direct
protein-protein interaction, rather than by competing for DNA-
binding sites and/or by activating transcription of another cellular
protein.
In contrast, we found that BZLF1 does not affect Oct-2 DNA-
binding to either a cellular promoter, Gadd45a, or to the FR
repeats in the EBV genome. In addition, BZLF1 was not found
complexed to Oct-2 responsive promoters in the presence of Oct-
2. These results suggest that BZLF1 may not globally regulate the
ability of Oct-2 to activate Oct-2-responsive genes. Somewhat
surprisingly, few (if any) genes in the human genome have been
shown to require Oct-2 for their expression. Thus dissecting the
effect (if any) of BZLF1 on Oct-2 mediated transcription will
require further study.
To determine whether endogenous Oct-2 expression contrib-
utes to viral latency in EBV-infected B cells, we used shRNA
vectors to knockdown endogenous Oct-2 in three different BL
lines (MutuI, KemI, and Raji) and an LCL line (Figure 8). Loss of
endogenous Oct-2 expression greatly increased the level of
constitutive lytic viral protein expression in two different BL lines
with type I latency (MutuI and KemI), as well as the ability of
TPA/sodium butyrate treatment to induce lytic viral protein
expression in the type III LCL line and Raji cells (a BL line with
type III latency). Loss of endogenous Oct-2 expression in MutuI
cells also results in increased RNA levels of many early and late
lytic viral genes. Importantly, these results confirm that Oct-2
promotes viral latency when expressed at normal levels in B cells in
the context of the intact virus, and in cells containing either type I
or type III latency.
Similar to our finding here that Oct-2 promotes EBV latency in
B cells; Oct-2 was recently reported to promote viral latency of
another human gammaherpesvirus, KSHV [70]. Interestingly,
although both viruses use the B-cell specific Oct-2 transcription
factor to achieve viral latency in B cells, the mechanisms by which
Oct-2 promotes latency for each virus are quite distinct. While the
Oct-2 effect on EBV appears to be primarily mediated through the
direct interaction between BZLF1 and Oct-2, and does not require
Oct-2 DNA-binding activity, the inhibitory effect of Oct-2 on
KSHV lytic reactivation requires Oct-2 DNA-binding activity and
is thought to be mediated by direct Oct-2 binding to the KSHV IE
ORF50 promoter [70]. Likewise, although both KSHV and EBV
use Oct-1 as a positive regulator of viral reactivation, the
mechanism(s) for the Oct-1 effect are somewhat different for each
virus [55,59,60]. Furthermore, both viruses use the XBP-1
transcription factor as a means to tie viral reactivation to plasma
cell differentiation [44,45,84].
condition, quantified using ImageJ software, is depicted in a bar graph at the bottom of the gel; the level of binding obtained with the full-length (1–
245) BZLF1 protein is set at 100 percent. (C) GST pull-down assays were performed using GST, GST-BZLF1, or GST-Oct-2 fusion proteins incubated
with
35S-labeled, in vitro-translated wild-type BZLF1 or mutant BZLF1 (Y200E/L225E) protein. Twenty percent of the direct load was used for
autoradiography. (D) Schematic of the Oct-2 protein POU specific domain (POUs), linker region (L), and POU homeodomain (POUh). Numbers
represent amino acid positions. Various Oct-2 truncation proteins used in subsequent GST pull-down assays are also depicted. (E) GST pull-down
assays were performed using GST, GST-BZLF1, or various GST-Oct-2 truncation fusion proteins incubated with
35S-labeled, in vitro-translated BZLF1
protein. Twenty percent of the direct load was used for autoradiography. The amount of BZLF1 binding in each condition, quantified using ImageJ
software, is depicted in a bar graph at the bottom of the gel; the level of binding obtained with Oct-2 (179–343) protein is set at 100 percent. (F) GST
pull-down assays were performed using GST or GST-BZLF1 fusion protein incubated with
35S-labeled, in vitro-translated (full-length) wild-type Oct-2
or mutant Oct-2 (D262–302) protein. Twenty percent of the direct load was used for autoradiography. (G) HONE-Akata cells were transfected with
5 ng BZLF1, 50 ng wild-type Oct-2, 50 ng mutant Oct-2 (D262–302), or control vectors as indicated. Immunoblot analysis was performed two days
after transfection to compare levels of transfected BZLF1 and Oct-2, as well as the level of BMRF1 derived from the endogenous viral genome. b-actin
served as a loading control.
doi:10.1371/journal.ppat.1002516.g006
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PLoS Pathogens | www.plospathogens.org 9 February 2012 | Volume 8 | Issue 2 | e1002516Figure 7. Oct-2 DNA-binding activity is not required for Oct-2 inhibition of BZLF1 function. (A) (Left panel) An EMSA was performed
using in vitro-translated wild-type or mutant Oct-2 (Q221A) protein and a
32P-labelled oligonucleotide probe containing the consensus Oct-2 binding
site. Protein-DNA complexes are indicated by arrows. (Right panel) Immunoblot analysis was performed to compare the levels of wild-type and
mutant Oct-2 (Q221A) in the in vitro-translated samples. (B) HONE-Akata cells were transfected with 5 ng BZLF1, 500 ng wild-type Oct-2, 500 ng
mutant Oct-2 (Q221A), or control vectors as indicated. Immunoblot analysis was performed two days after transfection to compare levels of
transfected BZLF1 and Oct-2, as well as the levels of BMRF1 and BRLF1 protein derived from the endogenous viral genome. b-actin served as a
loading control. (C) EBV-negative BJAB cells were transfected with a BMRF1p-luciferase construct in the presence or absence of co-transfected BZLF1
(30 ng), wild-type Oct-2 (1470 ng), two different mutant Oct-2 proteins (Oct-2 Q221A or Oct-2 D262–302) (1470 ng), or control vectors as indicated.
Oct-2 Promotes EBV Latency
PLoS Pathogens | www.plospathogens.org 10 February 2012 | Volume 8 | Issue 2 | e1002516B-cell differentiation into plasma cells (which is associated with
lytic viral reactivation) results in loss of Oct-2 expression [76].
Interestingly, we found that Oct-2 expression was also rather
dramatically decreased following treatment of EBV-positive BL
cell lines with two different lytic-inducing stimuli (stimulation of
the B-cell receptor with anti-IgG and treatment of cells with TPA/
sodium butyrate) (Figure 9). Partial re-expression of Oct-2 (via
lentivirus vectors) during TPA/sodium butyrate treatment of Raji
cells decreased the amount of induced lytic viral protein
expression, consistent with a role of Oct-2 loss in lytic gene
reactivation. Furthermore, the Oct-2 decrease following anti-IgG
treatment occurs prior to the maximal induction of the EBV
BMRF1 early gene. Our results also show that the mechanism(s)
by which anti-IgG and TPA/sodium butyrate reduce endogenous
Oct-2 expression appears to be at the RNA level. Since anti-IgG
treatment produced a similar effect in EBV-negative and EBV-
positive Akata cells, the reduced Oct-2 expression following this
treatment does not require an EBV-encoded gene product. In any
event, the finding that both anti-IgG and TPA/sodium butyrate
reduce Oct-2 expression in EBV-infected B cells suggests that loss
of Oct-2 expression is one mechanism by which these agents
induce lytic reactivation in B cells, in addition to their ability to
activate BZLF1 gene expression.
Oct-2 has been previously proposed to regulate the type of EBV
latency through regulation of the viral Cp [75]. According to this
model, Oct-2 acts as a repressor of the Cp when bound to the
upstream element FR, and B cells with high Oct-2 expression are
predicted to exhibit type I latency, whereas cells with low Oct-2
expression are predicted to have type III latency. However,
another report suggested that Oct-2 binding to the FR elements
activates the Cp [72]. Here we found that knockdown of Oct-2
expression in cells with both type I latency and type III latency
decreases EBNA1 protein expression through an apparently
largely post-transcriptional mechanism (Figure 8E and Figure 10).
Since the results of the previous papers were based on Oct-2 over-
expression assays using reporter gene constructs, rather than Oct-2
knockdown studies in the context of the endogenous genome, we
believe our studies are more likely to reflect the true effect of Oct-2
on EBV latent protein expression. Nevertheless, it is likely that the
cellular level of Oct-2 transcriptional co-repressors (such as TLE1/
2) [74] versus co-activators (such as Bob-1) [72], as well as the
methylation state of the viral Cp, may influence the effects of Oct-
2 on EBNA1 transcription. Additional studies will be necessary to
determine the exact mechanism(s) by which Oct-2 regulates
EBNA1 RNA and protein expression during type I versus type III
latency. It is unknown whether lytic viral proteins play any role in
mediating the post-transcriptional loss of EBNA1 expression.
In summary, our results here identify the B-cell specific cellular
transcription factor, Oct-2, as being a potent negative regulator of
EBV lytic reactivation. In contrast, our recent studies show that
Oct-1 interacts with, and activates, the BRLF1 protein, which
thereby promotes lytic viral reactivation. Our findings suggest a
model in which the relative levels of Oct-1 versus Oct-2 influence
whether EBV infection is latent versus lytic via their effects on
BRLF1 and BZLF1 respectively (Figure 11). In addition, our
findings suggest that Oct-2 may promote the establishment of EBV
latency not only by inhibiting lytic gene expression, but also by
increasing EBNA1 protein expression. We propose that Oct-2
plays a key role in allowing EBV to establish latency in a B-cell
dependent manner.
Materials and Methods
Cell lines and culture
EBV-negative HeLa cells were maintained in DMEM supple-
mented with 10% fetal bovine serum (FBS) and 1% penicillin/
streptomycin (pen/strep). EBV-negative HONE-1 cells (a gift from
Ron Glaser, The Ohio State University) and BJAB cells (obtained
from the ATCC) were maintained in RPMI 1640 supplemented
with 10% FBS and 1% pen/strep. HONE-Akata (a gift from
Lawrence Young, University of Birmingham) and CNE-2 Akata
cells (a gift from K. W. Lo at The Chinese University of Hong
Kong [received via Diane Hayward]) are nasopharyngeal
carcinoma (NPC) epithelial cell lines super-infected with the
Akata strain of EBV and were maintained in RPMI 1640
supplemented with 10% FBS, 1% pen/strep, and G418 (400 mg/
mL). Both HONE-Akata and CNE-2 Akata cells are examples of
type I latency cell lines. Akata (-) cells are an EBV-negative BL cell
line that were maintained in RPMI 1640 supplemented with 10%
FBS and 1% pen/strep. Akata-EBV+ cells (a gift from Kenzo
Takada at Hokkaido University [received via Bill Sugden]) are a
type I latency, BL cell line super-infected with the Akata strain of
EBV and maintained in RPMI 1640 supplemented with 10%
FBS, 1% pen/strep, and G418 (400 mg/mL). Raji cells (ATCC),
an EBV-positive type III latency BL cell line, were maintained in
RPMI 1640 supplemented with 10% FBS and 1% pen/strep.
MutuI and KemI cells (gifts from Jeff Sample, Penn State) are
EBV-positive type I latency BL cell lines and were maintained in
RPMI 1640 supplemented with 10% FBS and 1% pen/strep. LCL
cells, an early passage type III latency lymphoblastoid B-cell line
transformed with the B95.8 strain of EBV, were maintained in
RPMI 1640 supplemented with 10% FBS and 1% pen/strep. The
cell type and viral latency status of the various cell lines used in this
paper are summarized in Table S1.
Plasmids, cloning, and site-directed mutagenesis
Plasmid DNA was purified on maxi-prep columns according to
the manufacturer’s protocol (Qiagen). pSG5 was obtained from
Stratagene. The SG5-BRLF1 expression vector, a gift from S.D.
Hayward, Johns Hopkins University, contains the genomic
BRLF1 downstream of the simian virus 40 (SV40) promoter in
the pSG5 vector. BZLF1 cDNA (a gift from Paul Farrell, Imperial
The fold luciferase activity for each condition is shown relative to control vector; the value for the activity of the promoter construct plus the vector
control is set at 1. Values are given as means 6 standard deviations of results from two replicates. (D) A ChIP assay was performed using HONE-Akata
cells transfected with Flag-tagged-BZLF1, wild-type Oct-2, mutant Oct-2 (Q221A), or control vectors as indicated. Cross-linked DNA-protein complexes
were immunoprecipitated using antibodies against Flag (BZLF1) or an IgG control. Antibody-bound DNA sequences were then PCR-amplified using
primers spanning the EBV BRLF1, BMRF1, or SM promoters, the viral FR repeats, cellular Gadd45a promoter, or the GAPDH gene (negative control).
Binding bands were quantified using ImageJ software and represented as numerical values in bar diagrams in the lower panel. The amount of BZLF1
binding to each promoter in the presence or absence of wild-type or mutant Oct-2 (Q221A) was compared to input. (E) A ChIP assay was performed
using HONE-Akata cells transfected with 3 mg wild-type Oct-2 or mutant Oct-2 (Q221A), with or without 3 mg co-transfected BZLF1, or control vectors
as indicated. Cross-linked DNA-protein complexes were immunoprecipitated using antibodies against Oct-2 or an IgG control. Antibody-bound DNA
sequences were then PCR-amplified using primers spanning the cellular Gadd45a promoter, viral FR repeats, viral latency Qp, or the GAPDH gene
(negative control). Binding bands were quantified using ImageJ software and represented as numerical values in bar diagrams in the lower panel. The
amount of Oct-2 binding to each DNA region in the presence or absence of BZLF1 was compared to input.
doi:10.1371/journal.ppat.1002516.g007
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BZLF1 cDNA, which was also used to in vitro translate the BZLF1
protein. Flag-tagged-BZLF1, a gift from Paul Lieberman (Wistar
Institute) has BZLF1 cDNA inserted into a p3XFLAG-myc-
CMV24 vector (Sigma) for mammalian cell expression of a Flag-
tagged-BZLF1 protein. The pSG5-Oct-2 expression vector was
cloned by excising Oct-2 from pCGN-Oct-2 (a gift from Winship
Herr, Cold Spring Harbor Laboratory) [85] and inserting it into a
modified pSG5 vector (a gift from S.D. Hayward, Johns Hopkins
University) using XbaI and BglII restriction sites. Plasmids pSG5-
BZLF1 Y200E/L225E and pSG5-Oct-2 Q221A were constructed
by using Stratagene QuikChange II XL Site-Directed Mutagenesis
Kit and the following primer sets: BZLF1 Y200E forward 59-
GCCAAGTTTAAGCAACTGCTGCAGCACGAGCGTGAGG-
TCGCTGCTGCC-39 and reverse 59-GGCAGCAGCGACCT-
CACGCTCGTGCTGCAGCAGTTGCTTAAACTTGGC-39;
BZLF1 L225E forward 59-GCAGATGTGCCCAAGCGAGGA-
TGTTGACTCC-39 and reverse 59-GGAGTCAACATCCT-
CGCTTGGGCACATCTGC-39; Oct-2 Q221A forward 59-
GCATCAAGCTGGGCTTCACGGCGGGTGATGTGGGCC-
TGG-39 and reverse 59-CCAGGCCCACATCACCCGCCGT-
GAAGCCCAGCTTGATGC-39. pSG5-Oct-2 D262–302 was
generated using overlapping PCR as described previously [86]
using the following primer sets: Oct-2 deletion primer A 59-
CCGCGTCTAGAATGGGGGCTCCAGAAATAAG-39, Oct-2
deletion primer B 59-GGCTTCTGGTTCGCGCTTGAGTC-
CAC-39, Oct-2 deletion primer C 59- GTGGACTCAAGCGC-
GAACCAGAAGCC-39, and Oct-2 deletion primer D 59-
CTGAGGGATCCTCAAGGCTGGTAAGGGGC-39. All Oct-
2 expression vectors contain the major B-cell form of Oct-2,
isoform 1.
pGEX-KG and pGST-Oct-2 were a gift from Eric Turner
(University of California-San Diego) [87]. pGST-BZLF1 was
constructed by inserting BZLF1 amino acids (aa) 1-245 into
pGEX-KG using SalI and SacI restriction sites. pGST-Oct-2
mutants were created by inserting Oct-2 aa179–220, aa221–261,
aa262–302, or aa303–343 into pGEX-KG using SalI and HindIII
restriction sites. pGST-BZLF1 1–140 was created by inserting
BZLF1 aa1–140 into pGEX-KG using SalI and SacI restriction
sites. All other pGST-BZLF1 mutants (140–180, 180–225, 140–
225, 160–225, and 170–225) were created by inserting the
corresponding BZLF1 amino acid sequences into pGEX-KG
using SalI and HindIII restriction sites. Oct-2 WT and Oct-2
Q221A were cloned into the BamHI and EcoRI sites of the
pCDH713 lentiviral vector (SBI, Cat# CD713B-1-SBI), under the
control of the murine stem cell virus (MSCV) promoter, to create
CDH713-Oct-2 WT and CDH713-Oct-2 Q221A.
The BRLF1p-luciferase reporter gene construct contains the
Akata strain BRLF1p sequence from 21069 to +37 (relative to the
BRLF1 transcription start site) inserted upstream of the luciferase
gene in pGL3-basic (Promega) and was constructed as previously
described [44]. The SMp, BMRF1p, and BALF2p-luciferase
reporter gene constructs contain the B95.8 strain sequence from
2595 to +15, 2553 to +16, and 2593 to +7 respectively (relative
to transcription start site) inserted upstream of the luciferase gene
in pGL3-basic using MluI and BglII restriction sites. The
BXLF1p-luciferase reporter gene construct contains the BXLF1
promoter sequence (from 144859 to 145545) from the EBV B95.8
genomic DNA inserted upstream of the luciferase gene in pGL3-
basic. The pGal4-BZLF1 (1–167) contains BZLF1 amino acids 1–
167 inserted into pSG424 (M. Green, University of Massachusetts
Medical Center), which contains the Gal4 DNA-binding domain.
pGal4-E1B-CAT (M. Green, University of Massachusetts Medical
Center) contains five copies of the Gal4 binding motif upstream of
the E1B minimal TATA promoter and CAT (chloramphenicol
acetyltransferase) reporter gene.
Glutathione S-transferase pulldown assays
GST expression vectors were propagated in DH5a E. coli
overnight. Cultures were diluted 1:10, grown 2 hours and then
induced using 0.4 mM IPTG for an additional 2 h. GST proteins
were collected by sonication followed by incubation with
glutathione-agarose beads (Sigma-Aldrich), rocking for 1 hour at
room temperature. The beads were washed 3 times in GST buffer
(20 mM HEPES [pH 7.7], 25 mM NaCl, 2.5 mM MgCl2,
0.1 mM EDTA, 1 mM dithiothreitol [DTT], 0.05% NP-40,
protease inhibitor complete) and added to
35S-labelled in vitro
translated protein. In vitro-translated proteins were generated using
TNT T7 Quick Coupled Transcription/Translation System
(Promega) in accordance with the manufacturer’s instructions.
The reaction mixture was incubated for 20 minutes with rocking
at room temperature. The beads were washed 3 times in GST
buffer. An equal volume of 26SDS-sample buffer was added and
proteins were extracted by heating at 95uC for 10 minutes.
Immunoprecipitation
HeLa cells were transiently transfected with BZLF1 and/or
Oct-2 expression vectors and then harvested 48 hours later.
Alternatively, MutuI cells were treated with 5 mg/mL TGF-b
(R&D Systems) for 48 hours. Cells were washed with 16PBS and
then incubated on ice with occasional rocking for 30 minutes in
NP-40 lysis buffer (150 mM NaCl, 1% NP-40, 50 mM Tris
[pH 8], and protease inhibitors). Cells were scraped into
microcentrifuge tubes, sonicated for 15 s, and then centrifuged
Figure 8. Loss of endogenous Oct-2 increases constitutive and induced lytic gene expression in EBV-infected B cells. (A) MutuI cells
were infected with a pool of five different lentivirus vectors directed against Oct-2, individual lentivirus vectors directed against Oct-2, or control
shRNAs. The cells were selected for 7 days using puromycin. Immunoblot analysis was performed to compare the levels of endogenous Oct-2, BRLF1,
BZLF1, BMRF1, and b-actin (loading control) in each condition. The level of Oct-2 in each condition was quantitated relative to the Control #2 (set at
100) and is shown as a numerical value below the Oct-2 immunoblot. (B–D) KemI, Raji, and LCL cells were infected with a pool of five different
lentivirus vectors directed against Oct-2 or control shRNAs and selected for 7 days using puromycin. The level of Oct-2 in each condition was
quantitated relative to the untreated shControl (set at 100) and is shown as a numerical value below the Oct-2 immunoblot. (B) The type I BL cell line,
KemI, was then subjected to immunoblot analysis to compare the levels of endogenous Oct-2, BZLF1, BMRF1, and b-actin (loading control) in both
shOct-2 knockdown and control conditions. (C) Raji, a type III BL cell line, was treated with increasing amounts of TPA alone (4 or 20 ng/mL) or TPA (4
or 20 ng/mL) and sodium butyrate (0.6 or 3 mM) as indicated. Immunoblot analysis was performed after 24 hours to compare the levels of
endogenous Oct-2, BZLF1, BMRF1, and b-actin (loading control) in each condition. (D) The type III lymphoblastoid cell line (LCL) was treated with
20 ng/mL TPA and 3 mM sodium butyrate for 48 hours to induce lytic reactivation, followed by immunoblot analysis for endogenous Oct-2, BZLF1,
BMRF1, and b-actin (loading control). (E) RNA was isolated from control and shOct-2 infected MutuI cells, reverse-transcribed into cDNA, and analyzed
for the level of viral gene expression using qRT-PCR as described in the Materials and Methods. Shown is a heatmap depicting the fold-activation of
gene expression in the shOct-2 MutuI cells relative to the control vector infected cells. The EBV genes are grouped according to their gene expression
profile (IE lytic, early lytic, late lytic, and latent). The fold gene activation is indicated by the color shade.
doi:10.1371/journal.ppat.1002516.g008
Oct-2 Promotes EBV Latency
PLoS Pathogens | www.plospathogens.org 13 February 2012 | Volume 8 | Issue 2 | e1002516at maximum speed for 10 minutes at 4uC. Normal rabbit serum
was added to the supernatant and incubated on ice 1 h. Protein
A/G PLUS agarose beads (sc-2003; Santa Cruz Biotechnology)
were added to preclear and the samples were rocked for an
additional hour at 4uC. Beads were spun down, and the
supernatant was divided for the appropriate conditions. 1 mgo f
antibody (or no antibody for the direct load) was added to each
sample and rocked at 4uC for 1 h. The antibodies used were as
follows: mouse anti-BZLF1 (sc-53904; Santa Cruz), rabbit anti-
Oct-2 (sc-233; Santa Cruz Biotechnology), control mouse IgG (sc-
2025), and control rabbit IgG (sc-2027). A/G beads were added
and rocked at 4uC for 2 h. Beads were spun down and washed
three times in NP-40 lysis buffer. An equal volume of 26 SDS-
sample buffer was added and proteins were extracted by heating at
95uC for 10 minutes.
Transient transfections
HONE-Akata cells were transfected using Lipofectamine 2000
Transfection Reagent (Invitrogen) according to the manufacturer’s
instructions. Each transfection experiment was performed at least
three separate times with similar results. In general, cells were
transfected in a 12-well dish with limiting amounts of BZLF1 or
BRLF1 (5 ng), wild-type Oct-2 or mutant Oct-2 Q221A (500 ng),
or control expression vectors (approximately 500 ng total DNA
Figure 9. Lytic reactivation stimuli decrease Oct-2 expression. (A) The EBV-negative B-cell line, Akata (-), and the EBV-positive B-cell line,
Akata-EBV+, were lytically induced with anti-IgG (20 mg/mL). Immunoblot analysis was performed two days after treatment to compare the levels of
endogenous Oct-1, Oct-2, viral BMRF1 and b-actin (loading control). (B) Akata-EBV+ cells were lytically induced with anti-IgG (20 mg/mL) and
harvested at 12, 24 and 48 hour intervals. Immunoblot analysis was performed to compare the levels of endogenous Oct-2, BMRF1, BZLF1, and b-
actin (loading control). Oct-2 protein bands were quantified using ImageJ software and represented as percentage decrease of Oct-2 expression
(relative to untreated cells at each time point) as shown below the Oct-2 immunoblot. (C) Raji cells were lytically induced with the chemical inducers
TPA (20 ng/mL) and sodium butyrate (3 mM). Immunoblot analysis was performed two days after treatment to compare the levels of endogenous
Oct-1, Oct-2, viral BMRF1 and b-actin (loading control). (D) The expression level of the Oct-2 gene was examined by RT-PCR in Akata-EBV+ and Raji
cells lytically induced either with anti-IgG (20 mg/mL) or chemical inducers (20 ng/mL TPA/3 mM sodium butyrate) for 48 hours. The b2-microglobulin
gene was used as a control. (E) Raji cells were infected with lentivirus vectors (CDH713) which express either wild-type Oct-2 or mutant Oct-2 (Q221A)
proteins driven by the MSCV (murine stem cell virus) promoter and selected for 7 days using puromycin. Cells were then treated with 20 ng/mL TPA
and 3 mM sodium butyrate for 24 hours to induce lytic reactivation. Immunoblot analysis was performed to compare the levels of Oct-2, BZLF1,
BRLF1, BMRF1, and b-actin (loading control). The amount of Oct-2 protein expression was quantitated using ImageJ software and represented as a
numerical value below the Oct-2 immunblot. The Oct-2 protein level in untreated cells infected with the control lentivirus was set at 100.
doi:10.1371/journal.ppat.1002516.g009
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of BZLF1 was cotransfected with or without 50 ng of wild-type or
mutant Oct-2 proteins.
Immunoblotting
Immunoblotting was performed as previously described [48,88].
Cell lysates were harvested in SUMO lysis buffer containing
proteasome inhibitor cocktail (Roche) and quantitated by SUMO
Protein Assay (BioRad). Equivalent amounts of protein were
separated in sodium dodecyl sulfate, 10% polyacrylamide gels and
transferred to membranes. Membranes were blocked in PBS
containing 5% milk and 0.1% Tween-20 solution and incubated
with primary antibody. The following antibodies were used: anti-
b-actin (Sigma; 1:5000), BMRF1 (Vector; 1:250), BRLF1 (Argene;
1:250), BZLF1 (Santa Cruz, sc-53904; 1:250), Oct-2 (Santa Cruz,
sc-233; 1:500), Oct-1 (Santa Cruz, sc-71744; 1:250), EBNA1
(clone no. IH4 EBNA1 [89]; 1:50), EBNA2 (Leica, clone no. PE2;
1:100), EBNA-LP (clone no. JF186, 1:100, gift from Paul Ling,
Baylor), LMP1 (Dako, CS.1–4; 1:100), MEF2D (Biosciences,
610774; 1:10,000), ZEB1 (a gift from R. Burgess; 1:250), and
pSMAD2 (Ser465/467) (Cell Signaling; 1:1,000). The secondary
antibodies used were HRP goat-anti-mouse (Fisher Scientific;
1:5,000), HRP goat-anti-rabbit (Fisher Scientific; 1:10,000), and
HRP donkey-anti-rat (Pierce; 1:5,000)
Virus lytic replication assays
Virus lytic replication titration assays were performed as
previously described [90]. CNE-2 Akata cells were transfected
using Lipofectamine 2000 Transfection Reagent (Invitrogen) in a
12-well dish with 5 ng BZLF1, 500 ng Oct-2, or vector controls.
After 48 h, the cells were washed with 16PBS and fresh RPMI
media was added to the cells. After 24 h, supernatant from the
transfected cells was collected and filtered through a 0.8-mm-pore-
size filter. The filtered virus was used to infect Raji cells (4610
5
cells/infection). Phorbol-12-myristate-13-acetate (TPA; 20 ng/
mL) and sodium butyrate (3 mM final concentration) were added
at 24 hours post-infection. Green fluorescent protein (GFP)-
positive Raji cells were counted 48 hours after infection to
determine viral titer. Each condition was performed in duplicate.
Reporter gene assays
All reporter gene constructs were methylated using M. SssI
(NEB) according to the manufacturer’s instructions and methyl-
ation was confirmed by digestion with the restriction enzyme
HpaII (NEB), which cleaves its recognition sequence only if the
DNA is not methylated at the cytosine residue within the CpG
motif. HONE-1 cells were transfected using Lipofectamine 2000
Transfection Reagent (Invitrogen) in a 12-well dish with 50 ng
luciferase construct, 5 ng BZLF1 or BRLF1, 100 ng Oct-2, or
control expression vectors (500 ng total DNA per well). BJAB cells
were also transfected using Lipofectamine 2000 Transfection
Reagent in a 12-well dish with 100 ng luciferase construct, 30 ng
Figure 11. Hypothesized model for Oct-1 and Oct-2 regulation
of EBV lytic reactivation. (A) Oct-1 enhances lytic reactivation
through a direct protein-protein interaction between Oct-1 and the IE
protein BRLF1, which promotes BRLF1 DNA-binding and tethers Oct-1
to viral DNA. (RRE; BRLF1 responsive element) (B) Oct-2 promotes
latency by interacting with the BZLF1 IE protein and inhibiting its DNA-
binding. (ZRE; BZLF1 responsive element).
doi:10.1371/journal.ppat.1002516.g011
Figure 10. Oct-2 knockdown decreases EBNA1 protein expres-
sion in cells with type I and type III latency. (A) Type I BL cell lines,
MutuI and KemI, and the type III lymphoblastoid cell line (LCL) were
infected with a pool of five different lentivirus vectors directed against
Oct-2, or control shRNAs. The cells were selected for 7 days using
puromycin. The expression levels of the latency proteins EBNA1, EBNA2,
EBNA-LP, and LMP1 were examined using immunoblot analysis. b-actin
expression was used as a loading control. (B) The level of the EBNA1
transcript was examined by RT-PCR in type III LCL and Raji cells which
were infected with a pool of five different lentivirus vectors directed
against Oct-2, or control shRNAs. The cells were selected for 7 days
using puromycin prior to RT-PCR analysis. The b2-microglobulin gene
was used as a control.
doi:10.1371/journal.ppat.1002516.g010
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total DNA per well). Cells were harvested 48 hours post-
transfection in Reporter Lysis 56 Buffer (Promega). Relative
luciferase units were measured in a BD Monolight 3010
Luminometer (BD Biosciences) using Promega Luciferase Assay
Reagent. Each condition was performed in duplicate. Extracts
were also subjected to immunoblotting to verify equivalent protein
levels.
CAT assays
HeLa cells were transfected using FuGENE6 Transfection
Reagent (Roche) according to the manufacturer’s instructions in a
60 mm dish with 1 mg Gal4-E1B-CAT plasmid, 2.5 mg pGal4-
BZLF1(1–167), 2.5 mg Oct-2, or control expression vectors (6 mg
total DNA per dish). After 48 h, cells were harvested in ice cold
0.25 M Tris [pH 7.5] plus protease inhibitors (Roche) and
subjected to freeze-thawing and centrifugation. The cell lysates
were incubated at 37uC with acetyl coenzyme A and
14C-labeled
chloramphenicol (Amersham Biosciences), as described previously
[91]. The activity of the E1B promoter was measured by
acetylation of chloramphenicol, and the percent acetylation was
quantitated by thin-layer chromatography followed by autoradi-
ography. The results were quantified using ImageQuant software
(Amersham Biosciences). Extracts were also subjected to immu-
noblotting to verify equivalent protein levels.
Chromatin immunoprecipitation (ChIP) assays
HONE-Akata cells were transfected in 10-cm dishes (0.5 mg
Flag-tagged BZLF1, 5 mg Oct-2, or control vector). Cells were
cross-linked in fresh 1% paraformaldehyde for 10 minutes at room
temperature. The cross-linking reaction was quenched using
125 mM glycine. Following cell lysis and DNA fragmentation by
sonication, DNA-protein complexes were immunoprecipitated
with anti-FLAG (Sigma; F1804), anti-Oct-2 (Santa Cruz; sc-233),
and control anti-IgG (Santa Cruz) antibodies. Immunoprecipitat-
ed DNA-protein complexes were washed using sequential low salt,
high salt, lithium chloride and TE wash buffers. Protein-DNA
cross-linking was reversed at 65uC overnight. DNA was purified
using the Qiagen Gel Extraction Kit. The presence of specific
DNA fragments in each precipitate was detected using PCR.
Primers used for amplifying the SM promoter were 59-CGTGA-
CATGGAGAAACTGGGGG-39 and 59-CCTCTTACATCAC-
TCACTGCACG-39; BMRF1 promoter 59-ATGCCCAGAAAC-
CTGAGCAAGTAGCC-39 and 59-CCTTGGTGGATGTGCG-
AGCCATAAAG-39; BRLF1 promoter 59-CTCTTACCTGC-
GTCTGTTTGTG-39 and 59-CTCTCTGCTGCCCACTCAT-
ACT-39; GAPDH 59-TCACCACCATGGAGAAGGCT-39 and
59-GCCATCCACAGTCTTCTGGG-39; Hs Gadd45a 59-CT-
CCTCTCAACCTGACTCCAGGAG-39 and 59-TCCGGGG-
TTATCCTGCCAAC-39; FR element 59-GACTCTGCTTTC-
TGCCGTCT-39 and 59-CCTAACCATCCTTTTGCCAA-39;
Qp 59- GACCACTGAGGGAGTGTTCCACAG -39 and 59-AC-
ACCGTGCGAAAAGAAGCAC-39.
EMSA
T4 Polynucleotide Kinase (NEB) and gamma-
32P-ATP (Perki-
nElmer) were used to label double-stranded, annealed DNA
oligonucleotides for use in DNA-protein binding experiments. The
Oct probe consisted of an 18-bp sequence containing the octamer
consensus sequence (underlined) surrounded by random nucleo-
tides (59-CAGTGATGCAAATCTTGT-39). The protein samples
used in electrophoretic mobility shift assays (EMSAs) were in vitro-
translated protein (made using TNT T7 Quick Coupled
Transcription/Translation System [Promega]).
Infection and packaging of lentivirus vectors
Lentiviral vectors expressing 5 different Oct-2 directed shRNAs
(target set RHS4533), and the universal negative control, pLKO.1
(RHS4080) were purchased from Open Biosystems (Thermo-
Scientific) and propagated according to the manufacturer’s
instructions. 293T cells were co-transfected with lentiviral vector(s)
expressing shRNA, or Oct-2 proteins (pCD713-Oct-2 WT and
Oct-2 mutant Q221A), plus DNA vectors encoding HIV Gag/Pol
and VSV-G (for the packaging of lentiviruses) in 10-cm dishes.
Media (containing lentivirus) was harvested 72 hours later and
filtered through 0.8-mm-pore-size filters. MutuI, KemI, Raji and
LCL cells were infected by incubation with filtered media
containing the lentivirus. After 72 hours, stable cell lines were
selected for 7 days by treatment with 1 mg/mL puromycin, at
which time the various experiments were performed.
RT-PCR
RNA was harvested from Akata-EBV+ cells (treated with or
without anti-IgG treatment) and Raji cells (treated with or without
TPA/sodium butyrate) after 48 hours using Qiagen RNeasy Mini
Kit according to manufacturer’s instructions. Isolated RNA was
quantitated and DNase treated. Reverse transcriptase (RT)-PCR
analysis was performed to determine the transcript levels of the
endogenous cellular Oct-2 and b2-microglobulin genes. PCR
primers used to detect Oct-2 transcript were 59- GGCCC-
TCAACCTGAGCTTCAAG-39 and 59- GATCAGCAGGATC-
TCCTCT-39; and b2-microglobulin transcript 59-TTCTGG-
CCTGGAGGGCATCC-39 and 59-ATCTTCAAACCTCCAT-
GATG-39.
Quantitative RT-PCR
Total RNA was isolated from 10‘6 cells per condition using
Triazol (Sigma-Aldrich) as previously described [92]. mRNA was
then enriched using Oligotex mRNA purification system (Qiagen)
according to manufacturer’s instructions. Reverse transcription
was performed using the High Capacity cDNA Reverse
Transcription Kit (ABI, cat# 4368814) according to manufactur-
er’s instructions. EBV genome wide quantitative real-time PCR
(qRT-PCR) was conducted as described previously at the UNC
Vironomics Core Facility [93,94]. All primers have a predicted
Tm of 6061uC and were purchased from MWG Operon Inc..
qRT-PCR was conducted on an LC480 LightCycler (Roche)
under universal cycling conditions with 26LightCycler 480 SYBR
Green I Master qPCR mix (Roche) as the method of detection.
The final primer concentration was 250 nM in a total 5 ml
reaction. Data was collected in duplicate for each sample. The
comparative Ct, or DDCt method was used to measure the fold-
changes in gene expression between samples.
Supporting Information
Figure S1 Effect of Oct-2 on MEF2D, SMAD2, and ZEB1.
Oct-2 levels were manipulated in B-cell lines (MutuI, KemI, LCL,
and Raji) by infecting with a pool of five different lentivirus vectors
directed against Oct-2, or control shRNAs. The cells were selected
for 7 days using puromycin prior to immunoblot analysis. Oct-2
levels were also manipulated in the epithelial line, HONE-Akata
(HA), by transfection with control vector or 500 ng of Oct-2 vector
(500 ng DNA/12-well dish). (A) The KemI control and Oct-2
deficient B-cell lines, as well as the Oct-2 transfected HONE-
Akata cells (HA), were examined by immunoblot for MEF2D
phosphorylation using an antibody which recognizes total
MEF2D. MEF2D phosphorylation was also examined in Akata-
EBV+ cells induced for 48 hours with anti-IgG to serve as a
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loading control. (B) MutuI, KemI, LCL, and Raji control and Oct-
2 deficient B-cell lines were examined by immunoblot for SMAD2
phosphorylation status using an antibody which recognizes
phospho-SMAD2. MutuI cells treated with 5 ug/mL of TGF-b
for 48 hours served as a positive control. b-actin served as a
loading control. (C) Raji and KemI control and Oct-2 deficient B-
cell lines, as well as HONE-Akata cells (HA) transfected with
control vector or 500 ng of Oct-2 vector (500 ng DNA/12-well
dish), were examined by immunoblot for ZEB1 expression. b-actin
served as a loading control.
(TIF)
Table S1 Cell types, EBV status, and EBV latency type
of cell lines used in this study.
(TIF)
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